4.3 Article

Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor-α inhibitor

Journal

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
Volume 13, Issue 3, Pages e16-e19

Publisher

WILEY-BLACKWELL
DOI: 10.1111/j.1756-185X.2010.01528.x

Keywords

ankylosing spondylitis; chronic necrotizing pulmonary aspergillosis; etanercept; tumor necrosis factor-alpha

Categories

Ask authors/readers for more resources

Tumor necrosis factor (TNF)-alpha is a pro-inflammatory cytokine that plays an important role in the pathogenesis of a variety of autoimmune diseases. TNF-alpha inhibitors have been shown to offer clinical benefits in the treatment of autoimmune and inflammatory disorders, including rheumatoid arthritis, ankylosing spondylitis (AS), and Crohn's disease. Occasionally, these agents have been associated with infectious complications because of their immunosuppressive activity. Globally, several cases of infections associated with TNF-alpha inhibitors have been reported. However, Aspergillus infection associated with etanercept is very rare. We report a case of chronic necrotizing pulmonary aspergillosis in a 51-year-old man with AS that developed after treatment with etanercept.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available